Merck & Company Inc (MRK) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Merck & Co., Inc. operates as a healthcare company worldwide.

Total Cash From Operating Activities Chart for Merck & Company Inc

Merck & Company Inc (MRK) operating cash flow for FY2025 was USD 16.5B, a -23.3% change from FY2024. Merck & Company Inc's operating cash flow grew from USD 1.4B in 1989 to USD 16.5B in 2025 (1093.0% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 9.9%, 10-year CAGR of 2.9%, 20-year CAGR of 3.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$361.02B
Implied Share Price
$146.33
Enterprise Value
$394.46B
Revenue (TTM)
$66.57B
EBITDA
$28.87B
Profit Margin
4.77%
Trailing P/E
116.13
Forward P/E
15.02
Price/Book (MRQ)
8.29
Price/Sales (TTM)
5.42
EV/EBITDA
27.38
EV/Revenue
5.93
Dividend Yield
2.36%
Book Value
$16.99
Free Cash Flow (FY2025)
$12.36B
Free Cash Flow Yield
3.42%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.